Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1681/ASN.2015030241 http://scihub22266oqcxt.onion/10.1681/ASN.2015030241 C4814189!4814189!26494833     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Am+Soc+Nephrol 2016 ; 27 (4): 1225-33 Nephropedia Template TP {{tp|p=26494833|t=2016. Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients |pdf=|usr=}}{{26494833}} gab.com Text Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients JO: J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=26494833 #FOAvip Safety concerns with erythropoietin analogues and intravenous (IV) iron for treatment of anemia in CKD necessitate development of safer therapies. Roxadustat (FG-4592) is an orally bioavailable hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that promotes coordinated erythropoiesis through HIF-mediated transcription. We performed an open-label, randomized hemoglobin (Hb) correction study in anemic (Hb?10.0 g/dl) patients incident to hemodialysis (HD) or peritoneal dialysis (PD). Sixty patients received no iron, oral iron, or IV iron while treated with roxadustat for 12 weeks. MeanąSD baseline Hb was 8.3ą1.0 g/dl in enrolled patients. Roxadustat at titrated doses increased mean Hb by ?2.0 g/dl within 7 weeks regardless of baseline iron repletion status, C-reactive protein level, iron regimen, or dialysis modality. MeanąSEM maximal change in Hb from baseline (?Hbmax), the primary endpoint, was 3.1ą0.2 g/dl over 12 weeks in efficacy-evaluable patients (n=55). In groups receiving oral or IV iron, ?Hbmax was similar and larger than in the no-iron group. Hb response (increase in Hb of ?1.0 g/dl from baseline) was achieved in 96% of efficacy-evaluable patients. Mean serum hepcidin decreased significantly 4 weeks into study: by 80% in HD patients receiving no iron (n=22), 52% in HD and PD patients receiving oral iron (n=21), and 41% in HD patients receiving IV iron (n=9). In summary, roxadustat was well tolerated and corrected anemia in incident HD and PD patients, regardless of baseline iron repletion status or C-reactive protein level and with oral or IV iron supplementation; it also reduced serum hepcidin levels. Twit Text FOAVip Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients ????J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=26494833 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26494833 #FOAvip English Wikipedia <ref>{{Cite pmid|26494833}}</ref> Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients #MMPMID26494833 Besarab A; Chernyavskaya E; Motylev I; Shutov E; Kumbar LM; Gurevich K; Chan DTM; Leong R; Poole L; Zhong M; Saikali KG; Franco M; Hemmerich S; Yu KHP; Neff TB J Am Soc Nephrol 2016[Apr]; 27 (4): 1225-33 PMID26494833show ga Safety concerns with erythropoietin analogues and intravenous (IV) iron for treatment of anemia in CKD necessitate development of safer therapies. Roxadustat (FG-4592) is an orally bioavailable hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that promotes coordinated erythropoiesis through HIF-mediated transcription. We performed an open-label, randomized hemoglobin (Hb) correction study in anemic (Hb?10.0 g/dl) patients incident to hemodialysis (HD) or peritoneal dialysis (PD). Sixty patients received no iron, oral iron, or IV iron while treated with roxadustat for 12 weeks. MeanąSD baseline Hb was 8.3ą1.0 g/dl in enrolled patients. Roxadustat at titrated doses increased mean Hb by ?2.0 g/dl within 7 weeks regardless of baseline iron repletion status, C-reactive protein level, iron regimen, or dialysis modality. MeanąSEM maximal change in Hb from baseline (?Hbmax), the primary endpoint, was 3.1ą0.2 g/dl over 12 weeks in efficacy-evaluable patients (n=55). In groups receiving oral or IV iron, ?Hbmax was similar and larger than in the no-iron group. Hb response (increase in Hb of ?1.0 g/dl from baseline) was achieved in 96% of efficacy-evaluable patients. Mean serum hepcidin decreased significantly 4 weeks into study: by 80% in HD patients receiving no iron (n=22), 52% in HD and PD patients receiving oral iron (n=21), and 41% in HD patients receiving IV iron (n=9). In summary, roxadustat was well tolerated and corrected anemia in incident HD and PD patients, regardless of baseline iron repletion status or C-reactive protein level and with oral or IV iron supplementation; it also reduced serum hepcidin levels. äRoxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patien(epmc).pdf DeepDyve Pubget Overpricing